JERUSALEM & BOSTON--(BUSINESS WIRE)--Hadasit, the technology transfer company of Hadassah Medical Organization in Jerusalem, Harvard Medical School (HMS) and Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School, announced today an equally owned joint scientific venture to develop a new orally administered therapeutic treatment for autoimmune diseases. The new product is a combination therapy that joins together both Hadasit and BWH/HMS intellectual property. This is the first official cooperation between Hadasit, Hadassah, Harvard Medical School and Brigham and Women’s Hospital.
